Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | MLYCD | O95822 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722498 | 0.89 | HDAC6 (0.77) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL13484343 | 0.85 | HDAC6 (0.63) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL9546920 | 0.85 | HDAC6 (0.63) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL17483892 | 0.83 | HDAC6 (0.70) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL8389571 | 0.83 | HDAC6 (0.68) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL4518870 | 0.81 | HDAC6 (0.71) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL2972720 | 0.81 | HDAC6 (0.67) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL13212977 | 0.81 | CA2 (0.69) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL9546986 | 0.81 | MMP13 (0.84) | HDAC6MLYCDCA2MMP13POLB | |
| SCHEMBL25123079 | 0.81 | SMN1; SMN2 (0.76) | HDAC6MLYCDCA2MMP13POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | HDAC6 1861/4885MLYCD 3257/4885CA2 4662/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | HDAC6 2510/4885MLYCD 2090/4885CA2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.